- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02360813
Cognitive Remediation Therapy Within a Secure Forensic Setting
Randomised Controlled Trial to Evaluate the Efficacy of Cognitive Remediation Within a Secure Forensic Setting for Schizophrenia Spectrum Patients
Study Overview
Status
Intervention / Treatment
Detailed Description
This is a single centre randomised clinical trial to evaluate the feasibility, effectiveness and patient satisfaction with cognitive remediation therapy within a secure forensic setting for patients diagnosed with schizophrenia or schizoaffective disorder.
The feasibility of the intervention will be assessed using key indicators such as rate of enrolment, retention of patients in the trial, blinding effectiveness, and completion rate of the primary outcome measure. The effectiveness of the intervention will be assessed using the MATRICS consensus cognitive battery, symptoms (PANSS and CAINS) and real world functioning (SOFAS: Social and occupational functioning assessment scale). The effect of cognitive remediation on violence risk (HCR-20), programme completion and recovery (Dundrum 3 & 4) will also be examined, where programme completion is a measure of attainments from participating in additional psychosocial interventions and recovery is a measure of stability of mental state.
Patient satisfaction with cognitive remediation therapy will be assessed using a consumer constructed interview developed by Rose et al (2008) and administered by a social worker not involved in the delivery of cognitive remediation.
The trial will take place at the Republic of Ireland's Central Mental Hospital (CMH). The CMH is the only secure forensic psychiatric hospital for the Republic of Ireland, a population of 4.6 million. CMH provides specialised care for adults who have a mental disorder and are at risk of harming themselves or others.
After a baseline assessment to ensure eligibility and to obtain consent, an estimated 60 patients will be randomised to receive fourteen weeks of cognitive remediation versus treatment as usual. Patients who receive treatment as usual will be offered cognitive remediation upon completion of the study. Patients allocated to cognitive remediation will receive three individual sessions of cognitive remediation a week and one group session, fifty-six sessions in total The focus of the group session is to normalise cognitive difficulties that patients may be experiencing, to receive support and to help generalise gains. The primary outcome measure the MATRICS composite score and secondary outcome measures to assess real world functioning, symptoms, violence risk, programme completion and recovery will be administered at baseline, the end of treatment and at six month follow up. Secondary measures will also include feasibility outcomes and patient satisfaction with cognitive remediation therapy. All evaluators of the effectiveness measures will be blind to participant treatment condition at the time of assessment.
The cognitive remediation therapy is a principle driven intervention consisting of nine treatment principles: Principle 1 refers to relationship building, Principle 2 refers to collaborative goal setting, Principle 3 involves the session structure, Principle 4 concerns the content of the sessions, Principle 5, concerns the pacing of sessions, Principle 6 involves scaffolding and errorless learning, Principle 7 refers to meta-cognitive strategies, Principle 8 involves generalisation of gains, finally Principle 9 refers to managing ambivalence. The actual therapy will involve the use of a combination on pen, paper and computerised materials to stimulate patient's cognitive capacity and to provide them with the opportunity to apply meta-cognitive strategies.
The investigators hypothesise that it is feasible to carry out a randomised controlled trial within a single centre forensic setting and that patients will report high rates of satisfaction with cognitive remediation. It is also hypothesised that patients receiving cognitive remediation therapy will have an improvement in cognitive performance (the primary outcome measure), real world functioning, symptoms and violence risk over time relative to patients receiving treatment as usual; specifically that there will be a treatment by time interaction. Furthermore it is hypothesised that these differences will be maintained at six month follow up after the end of treatment.
In addition it is hypothesised that patients receiving cognitive remediation will show an improvement over time on the Dundrum programme completion and recovery scales compared to those receiving treatment as usual.
While meta-analytic reviews have demonstrated that cognitive remediation therapy has a beneficial effect on the cognitive deficits experienced by patients with schizophrenia (Wykes et al 2011), to the best of our knowledge there has been no study with forensic mental health patients. The current study will help answer whether it is feasible to deliver cognitive remediation within a forensic mental health setting and whether it is acceptable to patients. The study aims to contribute to the evidence base for psychological interventions within a forensic setting and to answer the question as to whether cognitive remediation has a beneficial effect and if it does whether this effect is maintained over time.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Dublin, Ireland, D 14
- Central Mental Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- A Structured Clinical Interview for Diagnostic and Statistical Manual IV (SCID) diagnosis of schizophrenia or schizoaffective disorder.
Exclusion Criteria:
- Acutely psychotic, or judged too dangerous to participate in treatment, or being over 65 years of age.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cognitive Remediation Therapy
Principle driven cognitive remediation therapy, cognitive rehabilitation, cognitive training, cognitive enhancement.
|
Fifty-six sessions of principle driven cognitive remediation therapy.
Three individual sessions and one group session each week for approximately fourteen weeks.
Other Names:
|
Active Comparator: Treatment as Usual
Usual care.
|
Keep getting usual care.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The MATRICS Consensus Cognitive Battery (MCCB)
Time Frame: Group by time interaction: changes from baseline, to end of treatment (average 5 months)
|
Consensus neuropsychological assessment battery for cognitive deficits in schizophrenia
|
Group by time interaction: changes from baseline, to end of treatment (average 5 months)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Social and Occupational Functioning Assessment Scale (SOFAS)
Time Frame: Group by time interaction: changes from baseline, to end of treatment (average 5 months)
|
100 item rating scale for measuring real world functioning independent of symptoms
|
Group by time interaction: changes from baseline, to end of treatment (average 5 months)
|
Positive and Negative Syndrome Scale (negative and disorganized factors)
Time Frame: Group by time interaction: changes from baseline, to end of treatment (average 5 months)
|
Rating scale for assessing psychiatric symptoms associated with schizophrenia
|
Group by time interaction: changes from baseline, to end of treatment (average 5 months)
|
Clinical Assessment Interview for Negative Symptoms (CAINS)
Time Frame: Group by time interaction: changes from baseline, to end of treatment (average 5 months)
|
Rating scale for assessing the negative symptoms of schizophrenia
|
Group by time interaction: changes from baseline, to end of treatment (average 5 months)
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Historical Clinical and Risk Management -20 (HCR-20)
Time Frame: Group by time interaction: changes from baseline, to 12 months
|
Rating scale for assessing violence risk
|
Group by time interaction: changes from baseline, to 12 months
|
Dundrum Toolkit: Programme Completion and Recovery Scales
Time Frame: Group by time interaction: changes from baseline to 12 months
|
Rating scale for assessing progress and recovery within a forensic mental health setting
|
Group by time interaction: changes from baseline to 12 months
|
Patient satisfaction.
Time Frame: Average 5 months.
|
Consumer developed interview exploring patient satisfaction with cognitive remediation.
|
Average 5 months.
|
Feasibility outcome: rate of enrolment.
Time Frame: 12 months.
|
Willingness of forensic mental health patients to participate in study.
|
12 months.
|
Feasibility outcome: rate of retention.
Time Frame: 12 months.
|
Number of patients who complete the intervention.
|
12 months.
|
Feasibility outcome: blinding.
Time Frame: 12 months.
|
Number of patients in which the blind is broken compared to number of patients in the study.
|
12 months.
|
Completion rate of primary outcome measures
Time Frame: 12 months.
|
Number of successfully completed primary outcome measures.
|
12 months.
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Professor Harry G Kennedy, M.D., Central Mental Hospital and Department of Psychiatry, Trinity College Dublin.
- Study Director: Professor Gary Donohoe, Ph.D., Department of Psychiatry, Trinity College Dublin.
- Principal Investigator: Dr. Ken W O'Reilly, D.Psych.Sc., Central Mental Hospital and Department of Psychiatry, Trinity College Dublin.
Publications and helpful links
General Publications
- Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261-76. doi: 10.1093/schbul/13.2.261.
- Nuechterlein KH, Green MF, Kern RS, Baade LE, Barch DM, Cohen JD, Essock S, Fenton WS, Frese FJ 3rd, Gold JM, Goldberg T, Heaton RK, Keefe RS, Kraemer H, Mesholam-Gately R, Seidman LJ, Stover E, Weinberger DR, Young AS, Zalcman S, Marder SR. The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am J Psychiatry. 2008 Feb;165(2):203-13. doi: 10.1176/appi.ajp.2007.07010042. Epub 2008 Jan 2.
- Wykes T, Huddy V, Cellard C, McGurk SR, Czobor P. A meta-analysis of cognitive remediation for schizophrenia: methodology and effect sizes. Am J Psychiatry. 2011 May;168(5):472-85. doi: 10.1176/appi.ajp.2010.10060855. Epub 2011 Mar 15.
- Kring AM, Gur RE, Blanchard JJ, Horan WP, Reise SP. The Clinical Assessment Interview for Negative Symptoms (CAINS): final development and validation. Am J Psychiatry. 2013 Feb;170(2):165-72. doi: 10.1176/appi.ajp.2012.12010109.
- Davoren M, Abidin Z, Naughton L, Gibbons O, Nulty A, Wright B, Kennedy HG. Prospective study of factors influencing conditional discharge from a forensic hospital: the DUNDRUM-3 programme completion and DUNDRUM-4 recovery structured professional judgement instruments and risk. BMC Psychiatry. 2013 Jul 9;13:185. doi: 10.1186/1471-244X-13-185.
- Rybarczyk B. (2011). Social and Occupational Functioning Assessment Scale (SOFAS). Encyclopedia of Clinical Neuropsychology. p 2313
- Webster CD, Douglas KS, Eaves D, Hart SD. HCR-20: assessing risk for violence. Burnaby: Mental Health Law and Policy Institute, Simon Fraser University; 1997.
- Rose D, Wykes T, Farrier D, Doran AM, Sporel T & Bogner D (2008) What Do Clients Think of Cognitive Remediation Therapy?: A Consumer-Led Investigation of Satisfaction and Side Effects, American Journal of Psychiatric Rehabilitation. Rehabilitation, 11:2, 181-204.
- O'Reilly K, Donohoe G, O'Sullivan D, Coyle C, Corvin A, O'Flynn P, O'Donnell M, Galligan T, O'Connell P, Kennedy HG. A randomized controlled trial of cognitive remediation for a national cohort of forensic patients with schizophrenia or schizoaffective disorder. BMC Psychiatry. 2019 Jan 15;19(1):27. doi: 10.1186/s12888-019-2018-6.
- O'Reilly K, Donohoe G, O'Sullivan D, Coyle C, Mullaney R, O'Connell P, Maddock C, Nulty A, O'Flynn P, O'Connell C, Kennedy HG. Study protocol: a randomised controlled trial of cognitive remediation for a national cohort of forensic mental health patients with schizophrenia or schizoaffective disorder. BMC Psychiatry. 2016 Jan 13;16:5. doi: 10.1186/s12888-016-0707-y.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Central Mental Hospital
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Schizophrenia
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Bradley LegaRecruiting
-
All India Institute of Medical Sciences, BhubaneswarRecruitingTreatment Resistant SchizophreniaIndia
-
King's College LondonSouth London and Maudsley NHS Foundation TrustRecruitingTreatment-resistant Schizophrenia | Healthy Controls | Treatment-responsive SchizophreniaUnited Kingdom
-
University of Sao PauloUnknownRefractory Schizophrenia | Super Refractory SchizophreniaBrazil
-
Rakitzi, StavroulaActive, not recruiting
-
Peking UniversityNot yet recruitingTreatment-resistant Schizophrenia
-
Ohio State UniversityRecruitingTreatment-resistant SchizophreniaUnited States
-
University Hospital, BrestRecruitingSchizophrenia | Schizophrenia Prodromal | Schizophrenia, ChildhoodFrance
Clinical Trials on Cognitive Remediation Therapy
-
Yale UniversityCompletedCancer | Cancer of the ProstateUnited States
-
Gemma Garrido GarcíaCompleted
-
Fundació Sant Joan de DéuCompletedIndication for Modification of Patient Cognitive StatusSpain
-
Yale UniversityNational Institute on Drug Abuse (NIDA)CompletedSubstance-Related Disorders | Mental DisordersUnited States
-
Fraser HealthMinistry of Social Development and Poverty Reduction, British ColumbiaCompletedSchizophrenia and Related Disorders | Psychotic DisorderCanada
-
Assistance Publique - Hôpitaux de ParisCompleted
-
Centre for Addiction and Mental HealthCompletedSchizophrenia | Cognitive Deficit | Cognitive Remediation | Functional Impairment | Late Life SchizophreniaCanada
-
King's College LondonUnknownSchizophrenia Schizoaffective
-
Hospital Clinic of BarcelonaInstituto de Salud Carlos III; Centro de Investigación Biomédica en Red de...Completed
-
Stanford UniversityNational Institute of Mental Health (NIMH)CompletedAnorexia NervosaUnited States